---
title: "TRANSTHERA's core product, Tiengoti, publishes exploratory clinical results"
description: "TRANSTHERA announced that the exploratory Phase 2 results of its core product Tiengotine for cholangiocarcinoma conducted in the United States were published in The Lancet, Gastroenterology and Hepato"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270025011.md"
published_at: "2025-12-17T14:13:56.000Z"
---

# TRANSTHERA's core product, Tiengoti, publishes exploratory clinical results

> TRANSTHERA announced that the exploratory Phase 2 results of its core product Tiengotine for cholangiocarcinoma conducted in the United States were published in The Lancet, Gastroenterology and Hepatology. The study shows that Tiengotine can overcome the resistance of FGFR2 fusion-positive cholangiocarcinoma patients to FGFR inhibitors and demonstrates antitumor activity in other patients with FGFR gene alterations

TRANSTHERA-B (02617.HK) announced that recently, the exploratory Phase 2 results of its core product, Tiengotine, for cholangiocarcinoma conducted in the United States were published in The Lancet Gastroenterology & Hepatology. Tiengotine can overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma and has shown anti-tumor activity in other cholangiocarcinoma patients with FGFR gene alterations.

In this Phase 2, open-label, multicenter study, eligible cholangiocarcinoma patients included those with FGFR2 fusion and primary or acquired resistance to FGFR inhibitors, patients with other FGFR gene alterations, and FGFR wild-type patients

### Related Stocks

- [02617.HK - TRANSTHERA-B](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 濫竽充數現代版｜曾智華 | 曾智華在《星島日報》A7 版上被列為財經名家，分享其保守的理財策略。財富主要分配在政府年金、政府債券及幾隻穩定的股票，包括中電、港鐵、國泰航空及港交所。四隻股票在蛇年表現良好，均有升幅和穩定的息率。中電股價從 60.45 元升至 77 元， | [Link](https://longbridge.com/en/news/276041378.md) |
| 根據 Allied Market Research 的報告，全球基因分型市場預計到 2033 年將達到 616 億美元，年複合增長率為 13.8% | 根據 Allied Market Research 的報告，全球基因分型市場在 2023 年的價值為 168 億美元，預計到 2033 年將達到 616 億美元，年均增長率為 13.8%。主要增長驅動因素包括遺傳疾病的增加、個性化醫療的轉變 | [Link](https://longbridge.com/en/news/276066747.md) |
| 翰森製藥的關鍵肺癌藥物奧莫替尼獲得歐盟批准 | 翰森製藥獲得歐盟對關鍵肺癌藥物阿莫雷替尼的批准 | [Link](https://longbridge.com/en/news/276393466.md) |
| 09:25 ET 基因預測公司任命 Santiago Munné 博士擔任首席科學官 | Genomic Prediction, Inc. 任命 Santiago Munné 博士為首席科學官。Munné 博士是生殖遺傳學領域的領導者，擁有超過 30 年的經驗，包括開創性地進行胚胎植入前基因檢測。他將負責公司的科學戰略和創新計劃 | [Link](https://longbridge.com/en/news/276240168.md) |
| 著名的原告律師 Jeffrey Rasansky 再次榮獲 Lawdragon 的榮譽 | 著名的原告律師傑弗裏·拉薩斯基（Jeffrey Rasansky）連續第八年被評選為 Lawdragon 500 位領先的原告消費者律師名單。拉薩斯基因其在個人傷害、錯誤死亡和醫療事故方面的工作而受到認可，他強調卓越的客户服務，並擁有超過  | [Link](https://longbridge.com/en/news/276152684.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.